Previous Article | Next Article ![]()
J. Virol., Nov 1995, 6898-6903, Vol 69, No. 11
M Benkirane, M Hirn, D Carriere and C Devaux
We recently demonstrated that monoclonal antibody (MAb) 13B8-2, specific
for the immunoglobulin (Ig) complementary determining region 3 (CDR3)-like
region of the CD4 molecule, inhibits viral transcription in human
immunodeficiency virus (HIV)-infected CEM cells and HIV type 1 (HIV-1)
promoter activity. Here, we have studied the capacity of several MAb
specific for the D1 domain of CD4, including anti-CDR2-like (Leu-3a and
ST4) and anti-CDR3-like (13B8-2 and ST40) MAb, and for the D2 domain of CD4
(BL4) to inhibit both provirus transcription in HIV- 1LAI-infected CEM
cells and transcription of the chloramphenicol acetyltransferase (CAT) gene
under control of the HIV-1 long terminal repeat in transiently transfected
CEM cells. We found that HIV-1 promoter activity and provirus transcription
are inhibited only by MAb that bind to the CDR3-like region in domain 1 of
CD4. Moreover, we demonstrated that the Fab fragment of an anti-CDR3-like
region-specific anti-CD4 MAb is a powerful inhibitor of HIV-1 promoter
activity. These results have implications for understanding the role of the
CDR3-like region in CD4 T-cell signaling, which controls provirus
transcription.
Copyright © 1995, American Society for Microbiology
Functional epitope analysis of the human CD4 molecule: antibodies that inhibit human immunodeficiency virus type 1 gene expression bind to the immunoglobulin CDR3-like region of CD4
Laboratoire d'Immunologie des Infections Retrovirales, Centre National de la Recherche Scientifique UPR 9008-Institut National de la Sante et de la Recherche Medicale U249, Montpellier, France.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|